Source: Υπουργείο Υγείας (CY) Revision Year: 2022 Publisher: Viatris Healthcare Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, Dublin, Ireland
Lipidil NT 145 mg film-coated tablet.
| Pharmaceutical Form |
|---|
|
Film coated tablet. White, oblong, film-coated tablets engraved “145” on one side and “Fournier logo” on the other side. |
Each tablet contains 145.0 mg fenofibrate (nanoparticles).
Excipients with known effect: each tablet contains:
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fenofibrate |
Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III. |
| List of Excipients |
|---|
|
Core: Sucrose Coating: Polyvinyl alcohol |
Thermoformed blister strips (clear PVC/PE/PVDC sealed with aluminium complex).
Packs of 10 or 14 tablets.
Boxes of 10, 20, 28, 30, 50, 84, 90, 98 and 100 tablets.
Hospital pack sizes: 280 (10 × 28) and 300 (10 × 30) tablets.
Not all pack sizes may be marketed.
Viatris Healthcare Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, Dublin, Ireland
21153
Date of First Authorisation: 19/12/11
Date of Latest Renewal: 12/04/17
| Drug | Countries | |
|---|---|---|
| LIPIDIL | Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Japan, Mexico |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
